Bengaluru-based Biocon Limited announced on December 6,‌ 2025, that it will ​acquire the remaining ‌stake held by Viatris inc. for $815 ⁤million. This move comes as Biocon prepares to revive its initial public offering (IPO)⁤ plans, following a period of integrating its recently acquired⁢ biosimilars business‌ and restructuring its debt.

The acquisition will be funded through a combination of cash and a share swap. Biocon will pay⁤ $400 million in cash⁢ and $415 million in Biocon shares to‍ Viatris. To secure the⁤ cash component of the deal,⁣ biocon also plans to raise up to ₹4,500 crore (approximately $500 million USD) through a qualified Institutional Placement (QIP).

Biocon is a leading⁣ biopharmaceutical company focused on developing and manufacturing high-quality, affordable‌ biologics, including biosimilars⁢ and novel biologics used to treat illnesses such as cancer and ⁢autoimmune diseases.

Details of the Acquisition ⁣and‍ Funding

The deal signifies Biocon’s commitment to strengthening its position ⁣in the global biosimilars market.⁣ Biosimilars are essentially generic versions of biologic drugs, offering more affordable ⁤treatment options for patients. ⁤ The integration of the Viatris biosimilars business is a key step ⁤in Biocon’s‍ long-term growth strategy.

The QIP will allow Biocon to raise the necessary capital without significantly impacting its existing debt​ levels. ‍Qualified Institutional Placements are a common method for Indian companies to raise funds from institutional ‍investors.

Background on Biocon and Viatris

Biocon Limited,⁢ established in 1978 by Kiran Mazumdar-Shaw,‌ has grown into one of India’s largest biotechnology companies. The⁣ company focuses on developing ⁤innovative and⁤ affordable healthcare ‌solutions, with a‌ particular emphasis on diabetes, oncology, and immunology. Biocon’s official website provides further details on their product ‌portfolio and ​research initiatives.

⁣ <